IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · IEX Real-Time Price · USD
39.94
+1.32 (3.42%)
Apr 26, 2024, 4:00 PM EDT - Market closed
IDEAYA Biosciences Revenue
In the year 2023, IDEAYA Biosciences had annual revenue of $23.39M, a decrease of -54.08%. Revenue in the quarter ending December 31, 2023 was $3.92M, a -2.49% decrease year-over-year.
Revenue (ttm)
$23.39M
Revenue Growth
-54.08%
P/S Ratio
127.69
Revenue / Employee
$188,589
Employees
124
Market Cap
2.99B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
Dec 31, 2020 | 19.54M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 8.76B |
Amedisys | 2.24B |
LivaNova | 1.15B |
Azenta | 641.02M |
Amicus Therapeutics | 399.36M |
Immunocore Holdings | 249.43M |
TransMedics Group | 241.62M |
Arrowhead Pharmaceuticals | 181.74M |
IDYA News
- 1 day ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 3 days ago - IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study - PRNewsWire
- 5 days ago - IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer - PRNewsWire
- 26 days ago - IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event - PRNewsWire
- 6 weeks ago - IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PRNewsWire
- 7 weeks ago - IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events - PRNewsWire
- 2 months ago - IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - PRNewsWire
- 3 months ago - IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events - PRNewsWire